vs
Side-by-side financial comparison of MACROGENICS INC (MGNX) and STEM, INC. (STEM). Click either name above to swap in a different company.
STEM, INC. is the larger business by last-quarter revenue ($47.1M vs $41.2M, roughly 1.1× MACROGENICS INC). On growth, MACROGENICS INC posted the faster year-over-year revenue change (113.0% vs -15.6%). Over the past eight quarters, MACROGENICS INC's revenue compounded faster (112.8% CAGR vs 36.1%).
MacroGenics Inc is a clinical-stage biopharmaceutical firm specializing in the research and development of novel immunotherapies for cancer and autoimmune disorders. Its core product pipeline centers on monoclonal antibody-based treatments, with key programs targeting solid tumors and hematological malignancies, supported by partnerships with global pharmaceutical partners.
StemCells, Inc. is a public biopharmaceutical company headquartered in Newark, California, that is developing purified human neural stem cells (HuCNS-SCs) in the hopes of treating central nervous system disorders and paralysis. StemCells' HuCNS-SCs have the ability to differentiate into the three main types of cells found in the central nervous system: neurons, astrocytes and oligodendrocytes.
MGNX vs STEM — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $41.2M | $47.1M |
| Net Profit | — | $-16.0M |
| Gross Margin | — | 48.9% |
| Operating Margin | -29.3% | -17.7% |
| Net Margin | — | -33.9% |
| Revenue YoY | 113.0% | -15.6% |
| Net Profit YoY | — | 68.8% |
| EPS (diluted) | $-0.23 | $-4.40 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $41.2M | $47.1M | ||
| Q3 25 | $72.8M | $38.2M | ||
| Q2 25 | $22.2M | $38.4M | ||
| Q1 25 | $13.2M | $32.5M | ||
| Q4 24 | $19.4M | $55.8M | ||
| Q3 24 | $110.7M | $29.3M | ||
| Q2 24 | $10.8M | $34.0M | ||
| Q1 24 | $9.1M | $25.5M |
| Q4 25 | — | $-16.0M | ||
| Q3 25 | $16.8M | $-23.8M | ||
| Q2 25 | $-36.3M | $202.5M | ||
| Q1 25 | $-41.0M | $-25.0M | ||
| Q4 24 | — | $-51.1M | ||
| Q3 24 | $56.3M | $-148.3M | ||
| Q2 24 | $-55.7M | $-582.3M | ||
| Q1 24 | $-52.2M | $-72.3M |
| Q4 25 | — | 48.9% | ||
| Q3 25 | — | 35.5% | ||
| Q2 25 | — | 33.4% | ||
| Q1 25 | — | 32.4% | ||
| Q4 24 | 98.8% | -4.4% | ||
| Q3 24 | 99.8% | 21.2% | ||
| Q2 24 | 98.4% | 27.6% | ||
| Q1 24 | 97.0% | -95.0% |
| Q4 25 | -29.3% | -17.7% | ||
| Q3 25 | 25.6% | -33.6% | ||
| Q2 25 | -165.3% | -34.8% | ||
| Q1 25 | -323.1% | -65.0% | ||
| Q4 24 | -273.0% | -84.4% | ||
| Q3 24 | 48.9% | -493.2% | ||
| Q2 24 | -538.9% | -1705.5% | ||
| Q1 24 | -590.4% | -267.0% |
| Q4 25 | — | -33.9% | ||
| Q3 25 | 23.1% | -62.2% | ||
| Q2 25 | -163.0% | 527.8% | ||
| Q1 25 | -311.1% | -76.9% | ||
| Q4 24 | — | -91.6% | ||
| Q3 24 | 50.9% | -506.3% | ||
| Q2 24 | -515.6% | -1712.6% | ||
| Q1 24 | -573.3% | -283.9% |
| Q4 25 | $-0.23 | $-4.40 | ||
| Q3 25 | $0.27 | $-2.84 | ||
| Q2 25 | $-0.57 | $-1.79 | ||
| Q1 25 | $-0.65 | $-0.15 | ||
| Q4 24 | $-0.24 | $-15.29 | ||
| Q3 24 | $0.90 | $-18.24 | ||
| Q2 24 | $-0.89 | $-71.81 | ||
| Q1 24 | $-0.84 | $-0.46 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $57.2M | $48.9M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $55.6M | $-249.4M |
| Total Assets | $256.8M | $308.9M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $57.2M | $48.9M | ||
| Q3 25 | $80.1M | $43.1M | ||
| Q2 25 | $130.7M | $40.8M | ||
| Q1 25 | $145.6M | $58.6M | ||
| Q4 24 | $182.8M | $56.3M | ||
| Q3 24 | $179.6M | $75.4M | ||
| Q2 24 | $83.9M | $89.6M | ||
| Q1 24 | $80.4M | $112.8M |
| Q4 25 | $55.6M | $-249.4M | ||
| Q3 25 | $67.0M | $-235.7M | ||
| Q2 25 | $46.6M | $-214.1M | ||
| Q1 25 | $79.1M | $-417.5M | ||
| Q4 24 | $116.1M | $-398.4M | ||
| Q3 24 | $120.1M | $-344.1M | ||
| Q2 24 | $57.8M | $-203.2M | ||
| Q1 24 | $106.2M | $371.6M |
| Q4 25 | $256.8M | $308.9M | ||
| Q3 25 | $270.8M | $362.6M | ||
| Q2 25 | $245.4M | $379.2M | ||
| Q1 25 | $224.6M | $405.1M | ||
| Q4 24 | $261.7M | $437.4M | ||
| Q3 24 | $264.5M | $537.8M | ||
| Q2 24 | $201.1M | $691.5M | ||
| Q1 24 | $248.3M | $1.3B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $43.0M | $8.2M |
| Free Cash FlowOCF − Capex | $42.8M | — |
| FCF MarginFCF / Revenue | 103.8% | — |
| Capex IntensityCapex / Revenue | 0.6% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-83.0M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $43.0M | $8.2M | ||
| Q3 25 | $-30.2M | $11.4M | ||
| Q2 25 | $-47.0M | $-21.3M | ||
| Q1 25 | $-46.9M | $8.5M | ||
| Q4 24 | $-38.4M | $-14.7M | ||
| Q3 24 | $60.2M | $-9.4M | ||
| Q2 24 | $-44.5M | $-11.9M | ||
| Q1 24 | $-45.6M | $-621.0K |
| Q4 25 | $42.8M | — | ||
| Q3 25 | $-30.6M | — | ||
| Q2 25 | $-47.7M | — | ||
| Q1 25 | $-47.4M | — | ||
| Q4 24 | $-39.0M | — | ||
| Q3 24 | $59.6M | — | ||
| Q2 24 | $-45.5M | — | ||
| Q1 24 | $-47.1M | — |
| Q4 25 | 103.8% | — | ||
| Q3 25 | -42.0% | — | ||
| Q2 25 | -214.5% | — | ||
| Q1 25 | -359.5% | — | ||
| Q4 24 | -201.7% | — | ||
| Q3 24 | 53.8% | — | ||
| Q2 24 | -421.6% | — | ||
| Q1 24 | -517.4% | — |
| Q4 25 | 0.6% | — | ||
| Q3 25 | 0.6% | — | ||
| Q2 25 | 3.2% | — | ||
| Q1 25 | 4.0% | — | ||
| Q4 24 | 3.2% | — | ||
| Q3 24 | 0.5% | — | ||
| Q2 24 | 9.6% | — | ||
| Q1 24 | 16.0% | — |
| Q4 25 | — | — | ||
| Q3 25 | -1.79× | — | ||
| Q2 25 | — | -0.11× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 1.07× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
MGNX
| Revenue From Collaborative Agreements | $20.3M | 49% |
| Contract Manufacturing | $11.3M | 27% |
| Other | $9.7M | 23% |
STEM
Segment breakdown not available.
